Article Sidebar

PDF
Date Published: 08/01/2022
Online Published: 08/01/2022
Abstract Views: 168
Views PDF: 110
DOI: https://doi.org/10.55046/vjrnm.44.11.2021
Issue
No. 44 (2021)
Section
Scientific research
How to Cite
Dam, P. T., Vu, D. L., Trinh, H. C., & Le, V. K. (2022). Efficacy of radioembolization with Yttrium-90 for treatment hepatocellular carcinoma. Vietnamese Journal of Radiology and Nuclear Medicine, 44, 47-53. https://doi.org/10.55046/vjrnm.44.11.2021

Efficacy of radioembolization with Yttrium-90 for treatment hepatocellular carcinoma

Dam Phuong Thao, Vu Dang Luu, Trinh Ha Chau, La Van Khang

Main Article Content

Abstract

Background: Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related deaths worldwide. Radioembolization with Yttrium-90 is a safe, effective locoregional therapy for unresectable HCC.
Purpose: This study aimed to evaluate the safety and efficacy of radioembolization with Yttrium-90 for the treatment of HCC.
Materials and methods: A total of 93 patients were diagnosed with HCC and treated by radioembolization with Yttrium-90 from 2013 to 2021 at Bach Mai Hospital. Radiographic findings on computed tomography (CT) or magnetic resonance imaging (MRI) were assessed by using modified Response Evaluation Criteria in Solid Tumors (mRECIST). Patient survival was assessed using the Kaplan-Meier method, and prognostic factors affecting survival were assessed using Cox proportional hazards regression.
Results: The mean age of 93 patients was 59.0±9.8 years. Mean tumors diameter was 6.5 ± 2.7 cm, the mean of tumor marker AFP is 1812 ± 6577 ng/ml. Complete response and partial response to treatment were observed in 21 (40.4%) and 15 patients (28.8%) of 52 follow-up patients. The median overall survival (OS) was 12.0 [95% CI: 5.0-25.0] months. Factors associated with longer OS included BCLC stage A-B, ECOG 0 and no portal vein thrombosis.
Conclusion: Radioembolization with Y-90 is safe and effective in patients with unresectable HCC. BCLC stage A-B, ECOG 0 and no portal vein thrombosis were positive prognostic factors

Article Details

Keywords

Hepatocellular carcinoma, radioembolization, Selective internal radiation therapy, Yttrium-90, Tumor response

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209-249. doi:10.3322/caac.21660
2. Riaz A, Lewandowski RJ, Kulik LM, et al. Complications Following Radioembolization with Yttrium-90 Microspheres: A Comprehensive Literature Review. Journal of Vascular and Interventional Radiology. 2009;20(9):1121-1130. doi:10.1016/j.jvir.2009.05.030
3. Rana N, Ju AW, Bazylewicz M, et al. Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma Who have Previously Received Sorafenib. Front Oncol. 2013;3. doi:10.3389/fonc.2013.00323
4. Saini A, Wallace A, Alzubaidi S, et al. History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma. JCM. 2019;8(1):55. doi:10.3390/jcm8010055
5. Mai Trọng Khoa. “Đánh giá kết quả điều trị khối u ác tính tại gan bằng xạ trị trong chọn lọc với hạt vi cầu phóng xạ Y-90 tại Bệnh viện Bạch mai.2013.
6. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes. Gastroenterology. 2010;138(1):52-64. doi:10.1053/j.gastro.2009.09.006
7. Van Thai N, Thinh NT, Ky TD, et al. Efficacy and safety of selective internal radiation therapy with yttrium-90 for the treatment of unresectable hepatocellular carcinoma. BMC Gastroenterol. 2021;21(1):216. doi:10.1186/s12876-021-01805-6
8. Meyer C, Pieper CC, Ahmadzadehfar H, et al. Yttrium-90 radioembolization of unresectable hepatocellular carcinoma - a single center experience. Onco Targets Ther. 2017;10:4773-4785. doi:10.2147/OTT.S137519
9. Sangro B, Carpanese L, Cianni R, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868-878. doi:10.1002/hep.24451
10. Ghosn M, Derbel H, Kharrat R, et al. Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria. Diagnostic and Interventional Imaging. 2021;102(1):35-44. doi:10.1016/j.diii.2020.09.004
11. Gabrielson A, Miller A, Banovac F, Kim A, He AR, Unger K. Outcomes and Predictors of Toxicity after Selective Internal Radiation Therapy Using Yttrium-90 Resin Microspheres for Unresectable Hepatocellular Carcinoma. Front Oncol. 2015;5. doi:10.3389/fonc.2015.00292
12. Sangro B, Carpanese L, Cianni R, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. Hepatology. 2011;54(3):868-878. doi:10.1002/hep.24451